Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes

@article{Barton2005Interleukin6AN,
  title={Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes},
  author={Beverly E. Barton},
  journal={Expert Opinion on Therapeutic Targets},
  year={2005},
  volume={9},
  pages={737 - 752}
}
  • B. Barton
  • Published 1 August 2005
  • Medicine, Biology
  • Expert Opinion on Therapeutic Targets
Interleukin-6 (IL-6) is a pleiomorphic cytokine whose growth factor properties play an important role in the development and progression of many types of cancer. IL-6 is produced in response to a variety of stimuli, and is required for the development of T and B lymphocytes to effector cells. In certain neoplasias, such as multiple myeloma, IL-6 is both produced and required for survival by the cancer cell itself. In other neoplasias, IL-6 may come from tissue surrounding the tumour. Thus… 
Interleukin-6 in oral diseases: a review.
TLDR
The present study reviews the available evidence regarding the association between IL-6 and a range of oral diseases including infections (periodontal disease and endodontic infections), immunologically mediated disorders (oral lichen planus and Sjögren's syndrome) and malignancy (oral cancer and precancer).
Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells
TLDR
The data showed that the inhibition of NF-κB activation abrogated MM cell proliferation induced by the IL-6 pathway, and might represent a promising therapeutic strategy for the treatment of MM.
Novel compound SK-1009 suppresses interleukin-6 expression through modulation of activation of nuclear factor-kappaB pathway.
TLDR
SK-1009 exerts a potent inhibitory effect on IL-6 expression, apparently mediated by modulation of activation of NF-κB transcription factor.
Interleukin-6 in aging and chronic disease: a magnificent pathway.
TLDR
The critical elements of the IL-6 signaling pathway are dissected and targets for intervention that are targeted by emerging drugs, some still on the horizon and others already being tested in clinical trials are pointed out.
Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism
TLDR
An interorgan system where stress-related hormones, IL-6, and GSH coordinately regulate metastases growth is described, following a circadian pattern and as compared to non-tumor controls, in mice bearing B16-F10 lung or liver metastases.
Production of cachexia mediators by Walker 256 cells from ascitic tumors
TLDR
Direct evidence of the release of proinflammatory cytokines and PGE2 by Walker 256 cells suggests that these mediators can drive the cachectic syndrome in the host, the effect being dependent on tumor development time.
STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance
  • B. Barton
  • Biology
    Expert opinion on therapeutic targets
  • 2006
TLDR
In various disease models ranging from tumours to autoimmune diseases, administration of STAT3-activating cytokines resulted in attenuation of immune responses, and persistently activating STAT3 in DCs may be a feasible strategy for controlling allograft rejection.
The Effects of Irradiation, Hyper-, and Hypothermia on Viability and Cytotoxicity of Natural Killer Cells
TLDR
The studies showed that the NK cell–enrichment methods used influenced the yield, purity, viability and cytotoxicity, and radiation sensitivity of the enriched NK cells.
Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells
TLDR
It is confirmed that lapatinib-resistant cells had elevated IL-6 expression and also maintained both stemness population and property and provided a potential strategy to overcome resistance via IL- 6 inhibition.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 222 REFERENCES
Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias.
  • T. Hirano
  • Medicine, Biology
    International journal of cell cloning
  • 1991
TLDR
It could be considered that continuous IL-6 gene expression plays an essential role in a multistep oncogenesis of plasma cell neoplasias.
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
TLDR
In six clinical studies of mAbs to IL-6 with BE-8 or CNTO 328 in patients with multiple myeloma, renal cell carcinoma, and B-lymphoproliferative disorders, anti-IL-6 mAb treatment decreased C-reactive protein levels in all patients, and the antibodies were well tolerated, and no serious adverse effects were observed in the vast majority of studies.
Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
TLDR
IL-6 receptor antagonists are pro-apoptotic factors for the IL-6-dependent human myeloma cell line XG-1 and their capacity to induce cell death is in direct relation to their affinity for IL- 6R alpha, degree of gp130 binding impairment, and efficiency to inhibit intracellular signaling events.
Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1
TLDR
The antiproliferative activity exerted by IL-6 mutants on the XG-1 cell line is documents, thus supporting the investigation of these molecules on primary MM cells.
Involvement of Interleukin-6 in the Autocrine Stimulation of Chronic Lymphocytic Leukemia B Cells by Tumor Necrosis Factor.
TLDR
Findings are suggestive of an autocrine or paracrine mechanism involving TNF and IL-6, the importance of the release and action of these cytokines in the regulation of B-CLL cell growth and malignant progression still remains to be elucidated.
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
TLDR
The present findings demonstrate that IL-6 is an autocrine/paracrine growth factor for DU145 and PC-3 prostate lines and protects the tumor cells against the cytotoxic effect of CDDP and VP-16 and its neutralization sensitizes the cells to cytotoxicity.
Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
  • M. Hayashi, M. Rho, S. Ōmura
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2002
TLDR
It is shown that MDL-A has a highly selective inhibitory effect on IL-6 and IL-11 activities by inhibiting a gp130 activity while suppressing bone loss in ovariectomized mice, anticipated as a lead compound for treatment of hormone-dependent postmenopausal osteoporosis, and as a new mechanism of action, gp130 blocking.
Interleukin 6 is essential for in vivo development of B lineage neoplasms
TLDR
The essential role of IL-6 in the development of B lineage tumors in vivo is defined and experimental support for continued efforts to modulate this cytokine in the treatment of appropriate human B cell malignancies is provided.
Interleukin-6 immunoreactivity in human tumors.
TLDR
It is demonstrated that most human tumors stain positively for IL-6, adding weight to the hypothesis that IL- 6 is a key cytokine that participates in the host-tumor interaction.
Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen.
TLDR
It is concluded that cachexia developed due to a systemic cytokine response induced by a tumour burden, and that IL-6-like cytokines contributed independently to lipid hypercatabolism in the aetiology of cancer cachexia.
...
1
2
3
4
5
...